AbbVie recently received the Food and Drug Administration's new breakthrough designation for its interferon-free hepatitis C treatment regimen. Although the product is groundbreaking and likely a future blockbuster, Motley Fool health care analyst David Williamson cautions investors not to get too excited over this development.
Watch the video below and find out why despite the new breakthrough status, AbbVie may have trouble competing.
In the pharma business, great success comes with a caveat. AbbVie is a perfect example, as investors in the new company are left wondering what the future holds once the company's golden goose, Humira, is cooked. The Fool's brand new premium report on the company answers the high-profile questions that AbbVie investors are asking. Simply click here now to claim your copy today.
Follow David on Twitter: @MotleyDavid.
The article A "Me Too" FDA Breakthrough originally appeared on Fool.com.
David Williamson has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences and Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.